TISIDB

Summary
Symbol	POU1F1
Name	POU class 1 homeobox 1
Aliases	GHF-1; POU1F1a; growth hormone factor 1; POU domain class 1, transcription factor 1; CPHD1; PIT1a; POU domai ......
Chromosomal Location	3p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF00046 Homeobox domain PF00157 Pou domain - N-terminal to homeobox domain
Function	Transcription factor involved in the specification of the lactotrope, somatotrope, and thyrotrope phenotypes in the developing anterior pituitary. Specifically binds to the consensus sequence 5'-TAAAT-3'. Activates growth hormone and prolactin genes (PubMed:22010633, PubMed:26612202).

> Gene Ontology [ TOP ]
Biological Process	GO:0001708 cell fate specification GO:0002521 leukocyte differentiation GO:0006066 alcohol metabolic process GO:0006109 regulation of carbohydrate metabolic process GO:0007568 aging GO:0008340 determination of adult lifespan GO:0010259 multicellular organism aging GO:0010675 regulation of cellular carbohydrate metabolic process GO:0010676 positive regulation of cellular carbohydrate metabolic process GO:0010919 regulation of inositol phosphate biosynthetic process GO:0016051 carbohydrate biosynthetic process GO:0019751 polyol metabolic process GO:0021536 diencephalon development GO:0021983 pituitary gland development GO:0021984 adenohypophysis development GO:0030098 lymphocyte differentiation GO:0030183 B cell differentiation GO:0030900 forebrain development GO:0032957 inositol trisphosphate metabolic process GO:0032958 inositol phosphate biosynthetic process GO:0032959 inositol trisphosphate biosynthetic process GO:0032960 regulation of inositol trisphosphate biosynthetic process GO:0032962 positive regulation of inositol trisphosphate biosynthetic process GO:0035264 multicellular organism growth GO:0035270 endocrine system development GO:0040014 regulation of multicellular organism growth GO:0040018 positive regulation of multicellular organism growth GO:0042113 B cell activation GO:0043255 regulation of carbohydrate biosynthetic process GO:0043567 regulation of insulin-like growth factor receptor signaling pathway GO:0043647 inositol phosphate metabolic process GO:0044262 cellular carbohydrate metabolic process GO:0044283 small molecule biosynthetic process GO:0044723 single-organism carbohydrate metabolic process GO:0045165 cell fate commitment GO:0045913 positive regulation of carbohydrate metabolic process GO:0045927 positive regulation of growth GO:0046165 alcohol biosynthetic process GO:0046173 polyol biosynthetic process GO:0048009 insulin-like growth factor receptor signaling pathway GO:0048638 regulation of developmental growth GO:0048639 positive regulation of developmental growth GO:0048732 gland development GO:0051169 nuclear transport GO:0060126 somatotropin secreting cell differentiation GO:0060133 somatotropin secreting cell development GO:0060732 positive regulation of inositol phosphate biosynthetic process GO:1901615 organic hydroxy compound metabolic process GO:1901617 organic hydroxy compound biosynthetic process GO:1902930 regulation of alcohol biosynthetic process GO:1902932 positive regulation of alcohol biosynthetic process
Molecular Function	GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001085 RNA polymerase II transcription factor binding GO:0001102 RNA polymerase II activating transcription factor binding GO:0001104 RNA polymerase II transcription cofactor activity GO:0001105 RNA polymerase II transcription coactivator activity GO:0001159 core promoter proximal region DNA binding GO:0001190 transcriptional activator activity, RNA polymerase II transcription factor binding GO:0001191 transcriptional repressor activity, RNA polymerase II transcription factor binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0003682 chromatin binding GO:0003713 transcription coactivator activity GO:0003714 transcription corepressor activity GO:0008134 transcription factor binding GO:0033613 activating transcription factor binding GO:0098811 transcriptional repressor activity, RNA polymerase II activating transcription factor binding
Cellular Component	GO:0005667 transcription factor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	POU1F1
Name	POU class 1 homeobox 1
Aliases	GHF-1; POU1F1a; growth hormone factor 1; POU domain class 1, transcription factor 1; CPHD1; PIT1a; POU domai ......
Chromosomal Location	3p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between POU1F1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	POU1F1
Name	POU class 1 homeobox 1
Aliases	GHF-1; POU1F1a; growth hormone factor 1; POU domain class 1, transcription factor 1; CPHD1; PIT1a; POU domai ......
Chromosomal Location	3p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of POU1F1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.52	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	POU1F1
Name	POU class 1 homeobox 1
Aliases	GHF-1; POU1F1a; growth hormone factor 1; POU domain class 1, transcription factor 1; CPHD1; PIT1a; POU domai ......
Chromosomal Location	3p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of POU1F1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.211	0.757
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.733	0.49
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.443	0.713
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0	1
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0	1
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.096	0.823
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.096	0.881
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.028	0.878

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of POU1F1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	1.4	6	0.177
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	1.7	5.7	0.231
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	20	0	20	0.294

Summary
Symbol	POU1F1
Name	POU class 1 homeobox 1
Aliases	GHF-1; POU1F1a; growth hormone factor 1; POU domain class 1, transcription factor 1; CPHD1; PIT1a; POU domai ......
Chromosomal Location	3p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of POU1F1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	POU1F1
Name	POU class 1 homeobox 1
Aliases	GHF-1; POU1F1a; growth hormone factor 1; POU domain class 1, transcription factor 1; CPHD1; PIT1a; POU domai ......
Chromosomal Location	3p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of POU1F1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by POU1F1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	POU1F1
Name	POU class 1 homeobox 1
Aliases	GHF-1; POU1F1a; growth hormone factor 1; POU domain class 1, transcription factor 1; CPHD1; PIT1a; POU domai ......
Chromosomal Location	3p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of POU1F1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	POU1F1
Name	POU class 1 homeobox 1
Aliases	GHF-1; POU1F1a; growth hormone factor 1; POU domain class 1, transcription factor 1; CPHD1; PIT1a; POU domai ......
Chromosomal Location	3p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of POU1F1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	POU1F1
Name	POU class 1 homeobox 1
Aliases	GHF-1; POU1F1a; growth hormone factor 1; POU domain class 1, transcription factor 1; CPHD1; PIT1a; POU domai ......
Chromosomal Location	3p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between POU1F1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	POU1F1
Name	POU class 1 homeobox 1
Aliases	GHF-1; POU1F1a; growth hormone factor 1; POU domain class 1, transcription factor 1; CPHD1; PIT1a; POU domai ......
Chromosomal Location	3p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting POU1F1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse POU1F1